NeuroScientific Biopharmaceuticals (NSB) H1 2026 earnings summary

Executive summary

• Focused on R&D of biomedical products for neurodegenerative and immune-mediated diseases, with key assets EmtinB and newly acquired StemSmart™.

• Initiated a clinical program for StemSmart™ in Crohn's disease under the TGA Special Access Scheme; four patients treated by period end.

• Advanced pre-clinical development of EmtinB for glaucoma, including formulation and safety studies.

• Appointed new CEO and CMO in July 2025 to strengthen leadership and clinical expertise.

• Partnered with Q-Gen Cell Therapeutics for technology transfer of StemSmart™ manufacturing.

Financial highlights

• Net loss for the half-year was $1,699,413, compared to $367,554 for the same period last year.

• Revenue comprised $118,396 in interest income and $317,905 from R&D tax incentives.

• Operating cash outflow was $908,396, up from $460,781 year-over-year.

• Cash and term deposits at period end totaled $6,357,373, down from $7,265,769 at June 2025.

• No dividends declared or paid during the period.

Outlook and guidance

• Directors consider the going concern basis appropriate, supported by working capital surplus and ability to raise funds or reduce costs.

• Continued focus on clinical and pre-clinical development of key assets and pursuit of commercial opportunities.